Publications

Jump to: 20192018 / 2017 / 2016 / 2015 / 2014 / 2012 / Before 2012

2019

Kuninty, P. R., Bansal, R., S., D. G., Mardhian, D. F., Schnittert, J., van Baarlen, J., Storm, G., Bijlsma, M., van Laarhoven, Metselaar, J. M., Kuppen, P. J. K., Vahrmeijer, A., Ostman, A., Sier, C. F. M. & Prakash, J.
ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer. 
Science Advances (in press)

Ozturk B, Dathathri E, Gabriel A, Ortiz Perez A, Storm G, Prakash J, Bansal R.
TG101348, a selective JAK2 antagonist ameliorates hepatic fibrogenesis in vivo.
FASEB J 2019 May 17:fj201900215RR. doi: 10.1096/fj.201900215RR

Heinrich MA, Liu W, Jimenez A, Yang J, Akpek A, Liu X, Pi Q, Mu X, Hu N, Schiffelers RM, Prakash J, Xie J, Zhang YS.
3D Bioprinting: from Benches to Translational Applications.
Small, 2019, Apr 29:e1805510. doi: 10.1002/smll.201805510.

Schnittert J, Bansal R, Mardhian DF, van Baarlen J, Östman A, Prakash J.
Integrin α11 in pancreatic stellate cells regulates tumor stroma interaction in pancreatic cancer. 
FASEB J. 2019 Feb 26:fj201802336R. doi: 10.1096/fj.201802336R.

Schnittert J, Bansal R, Prakash J.
Targeting Pancreatic Stellate Cells in Cancer.
Trends Cancer. 2019 Feb;5(2):128-142. doi: 10.1016/j.trecan.2019.01.001. Epub 2019 Feb 1.image
PMID: 30755305

Heinrich MA, Bansal R, Lammers T, Zhang YS, Michel Schiffelers R, Prakash J.
"3D-Bioprinted Mini-Brain: A Glioblastoma Model to Study Cellular Interactions and Therapeutics."
Adv Mater. 2019 Jan 31:e1806590. doi: 10.1002/adma.201806590. [Epub ahead of print]
PMID: 30702785

Nagórniewicz B, Mardhian DF, Booijink R, Storm G, Prakash J, Bansal R.
"Engineered Relaxin as theranostic nanomedicine to diagnose and ameliorate liver cirrhosis."
Nanomedicine. 2019 Jan 22;17:106-118.
PMID: 30677498

Mardhian DF., Storm G., Bansal R., Prakash J.
''Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo.''
J. Control. Release 2018 Oct 2;290:1-10. doi: 10.1016/j.jconrel.2018.09.031.
PMID: 30287265

Kurniawan DW., Jajoriya AK., Dhawan G., Mishra D., Argemi J., Bataller R., Storm G., Mishra DP., Prakash J., Bansal R.
''Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis.''
J. Control. Release 2018 Oct 28;288:227-238. doi: 10.1016/j.jconrel.2018.09.004. Epub 2018 Sep 13.
PMID: 30219279

Schnittert J., Heinrich MA., Kuninty PR., Storm G., Prakash J.
''Reprogramming tumor stroma using an endogenous lipid lipoxin A4 to treat pancreatic cancer''
Cancer Lett. 2018 Apr 28;420:247-258. doi: 10.1016/j.canlet.2018.01.072. Epub 2018 Feb 21.
PMID: 29408203

Schnittert J., Bansal R., Storm G., Prakash J.
''Integrins in wound healing, fibrosis and tumor stroma: High potential targets for therapeutics and drug delivery''
Adv Drug Deliv Rev. 2018 Feb 4. pii: S0169-409X(18)30028-0. doi: 10.1016/j.addr.2018.01.020. [Epub ahead of print]
PMID: 29414674

2017

Prakash J., Pinzani M.
''Fibroblasts and extracellular matrix: Targeting and therapeutic tools in fibrosis and cancer.''
Adv Drug Deliv Rev. 2017 Nov 1;121:1-2. doi: 10.1016/j.addr.2017.11.008.
PMID: 29191284

Bansal R., Nakagawa S., Yazdani S., van Baarlen J., Venkatesh A., Koh A.P., Song W.M., Goossens N., Watanabe H., Beasley M.B., Powell C.A,, Storm G., Kaminski N., van Goor H., Friedman S.L., Hoshida Y., Prakash J.
''Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases.''
Exp Mol Med. 2017 Nov 17;49(11):e396. doi: 10.1038/emm.2017.213.
PMID: 29147013

Binnemars-Postma K., Bansal R., Storm G., Prakash J.
''Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer.''
FASEB J. 2017 Oct 24. pii: fj.201700629R. doi: 10.1096/fj.201700629R.
PMID: 29066614

Prakash J.
''Cancer-Associated Fibroblasts: Perspectives in Cancer Therapy.''
Trends Cancer. 2016 Jun;2(6):277-279. doi: 10.1016/j.trecan.2016.04.005. Epub 2016 May 6.
PMID: 28741524

Yazdani S., Bansal R., Prakash J.
''Drug targeting to myofibroblasts: Implications for fibrosis and cancer.''
Adv Drug Deliv Rev. 2017 Nov 1;121:101-116. doi: 10.1016/j.addr.2017.07.010. Epub 2017 Jul 16. Review.
PMID: 28720422

Schnittert J., Kuninty P.R., Bystry T.F., Brock R., Storm G., Prakash J.
''Anti-microRNA targeting using peptide-based nanocomplexes to inhibit differentiation of human pancreatic stellate cells.''
Nanomedicine (Lond). 2017 May 19. doi: 10.2217/nnm-2017-0054.
PMID: 28524768

Strell C., Norberg K.J., Mezheyeuski A., Schnittert J., Kuninty P.R., Moro C.F., Paulsson J., Schultz N.A., Calatayud D., Löhr J.M., Frings O., Verbeke C.S., Heuchel R.L., Prakash J., Johansen J.S., Östman A.
''Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC.''
Br J Cancer. 2017 Jun 27;117(1):65-77. doi: 10.1038/bjc.2017.140. Epub 2017 May 18.
PMID: 28524160

Binnemars-Postma K., Storm G., Prakash J.
''Nanomedicine Strategies to Target Tumor-Associated Macrophages.''
Int J Mol Sci. 2017 May 4;18(5). pii: E979. doi: 10.3390/ijms18050979. Review.
PMID: 28471401

Öztürk Akcora B., Storm G., Prakash J., Bansal R.
''Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model.''
Sci Rep. 2017 Mar 14;7:44545. doi: 10.1038/srep44545.
PMID: 28291245

2016

Bansal R., Nagórniewicz B., Prakash J.
''Clinical Advancements in the Targeted Therapies against Liver Fibrosis.''
Mediators Inflamm. 2016;2016:7629724. doi: 10.1155/2016/7629724. Epub 2016 Nov 24. Review.
PMID: 27999454

Binnemars-Postma K.A., Ten Hoopen H.W., Storm G., Prakash J.
''Differential uptake of nanoparticles by human M1 and M2 polarized macrophages: protein corona as a critical determinant.''
Nanomedicine (Lond). 2016 Nov;11(22):2889-2902. Epub 2016 Oct 26.
PMID: 27780415

Priwitaningrum D.L., Blondé J.G., Sridhar A., van Baarlen J., Hennink W.E., Storm G., Le Gac S., Prakash J.
''Tumor stroma-containing 3D spheroid arrays: A tool to study nanoparticle penetration.''
J Control Release. 2016 Dec 28;244(Pt B):257-268. doi: 10.1016/j.jconrel.2016.09.004. Epub 2016 Sep 9.
PMID: 27616660

Hu Q., Rijcken C.J., van Gaal E., Brundel P., Kostkova H., Etrych T., Weber B., Barz M., Kiessling F., Prakash J., Storm G., Hennink W.E., Lammers T.
''Tailoring the physicochemical properties of core-crosslinked polymeric micelles for pharmaceutical applications.''
J Control Release. 2016 Dec 28;244(Pt B):314-325. doi: 10.1016/j.jconrel.2016.07.012. Epub 2016 Jul 9.
PMID: 27401327/a>

Prakash J., Pietras K.
''Editorial: Novel Targets and Targeting Technologies to Modulate Tumor Microenvironment.''
Front Oncol. 2016 May 17;6:121. doi: 10.3389/fonc.2016.00121. eCollection 2016. No abstract available.
PMID: 27242961

Kuninty P.R., Bojmar L., Tjomsland V., Larsson M., Storm G., Östman A., Sandström P., Prakash J.
''MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor.''
Oncotarget. 2016 Mar 29;7(13):16396-408. doi: 10.18632/oncotarget.7651.
PMID: 26918939

Kuninty P.R., Schnittert J., Storm G., Prakash J.
''MicroRNA Targeting to Modulate Tumor Microenvironment.''
Front Oncol. 2016 Jan 19;6:3. doi: 10.3389/fonc.2016.00003. eCollection 2016. Review.
PMID: 26835418

2015

Bansal R., van Baarlen J., Storm G., Prakash J.
''The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis.''
Sci Rep. 2015 Dec 14;5:18272. doi: 10.1038/srep18272.
PMID: 26658360

Hu Q., Rijcken C.J., Bansal R., Hennink W.E., Storm G., Prakash J.
''Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles.''
Biomaterials. 2015;53:370-8. doi: 10.1016/j.biomaterials.2015.02.085. Epub 2015 Mar 18.
PMID: 25890735

Oon C.E., Strell C., Yeong K.Y., Östman A., Prakash J.
''SIRT1 inhibition in pancreatic cancer models: contrasting effects in vitro and in vivo.''
Eur J Pharmacol. 2015 Jun 15;757:59-67. doi: 10.1016/j.ejphar.2015.03.064. Epub 2015 Apr 3.
PMID: 25843411

Hu Q., van Gaal E.V., Brundel P., Ippel H., Hackeng T., Rijcken C.J., Storm G., Hennink W.E., Prakash J.
''A novel approach for the intravenous delivery of leuprolide using core-cross-linked polymeric micelles.''
J Control Release. 2015 May 10;205:98-108. doi: 10.1016/j.jconrel.2014.12.023. Epub 2015 Jan 10.
PMID: 25583642

Poosti F., Bansal R., Yazdani S., Prakash J., Post E., Klok P., van den Born J., de Borst M.H., van Goor H., Poelstra K., Hillebrands J.L.
''Selective delivery of IFN-γ to renal interstitial myofibroblasts: a novel strategy for the treatment of renal fibrosis.''
FASEB J. 2015 Mar;29(3):1029-42. doi: 10.1096/fj.14-258459. Epub 2014 Dec 2.
PMID: 25466892

2014

Bansal R., Prakash J., De Ruiter M., Poelstra K.
''Targeted recombinant fusion proteins of IFNγ and mimetic IFNγ with PDGFβR bicyclic peptide inhibits liver fibrogenesis in vivo.''
PLoS One. 2014 Feb 24;9(2):e89878. doi: 10.1371/journal.pone.0089878. eCollection 2014.
PMID: 24587093

Bansal R., Prakash J., De Ruiter M., Poelstra K.
''Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo.''
J Control Release. 2014 Apr 10;179:18-24. doi: 10.1016/j.jconrel.2014.01.022. Epub 2014 Jan 31.
PMID: 24491909

2012

Bansal R., Tomar T., Ostman A., Poelstra K., Prakash J.
''Selective targeting of interferon γ to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth.''
Mol Cancer Ther. 2012 Nov;11(11):2419-28. doi: 10.1158/1535-7163.MCT-11-0758. Epub 2012 Aug 29.
PMID: 22933708

Poosti F, Yazdani S, Dolman ME, Kok RJ, Chen C, Ding G, Lacombe M, Prakash J,
van den Born J, Hillebrands JL, van Goor H, de Borst MH.
"Targeted inhibition of renal Rho kinase reduces macrophage infiltration and lymphangiogenesis in acute renal allograft rejection."
Eur J Pharmacol. 2012 Nov 5;694(1-3):111-9.
PMID: 22964464.

Poelstra K, Prakash J, Beljaars L.
"Drug targeting to the diseased liver."
J Control Release. 2012 Jul 20;161(2):188-97. Review.
PMID: 22370583.

van Beuge MM, Poelstra K, Prakash J.
Specific delivery of kinase inhibitors in nonmalignant and malignant diseases.
Expert Opin Drug Deliv. 2012 Jan;9(1):59-70. Review.
PMID: 22111941.

Before 2012

de Jong E, Winkel P, Poelstra K, Prakash J. Anticancer effects of
15d-prostaglandin-J2 in wild-type and doxorubicin-resistant ovarian cancer cells:
novel actions on SIRT1 and HDAC. PLoS One. 2011;6(9):e25192. doi:
10.1371/journal.pone.0025192. Epub 2011 Sep 21. PMID: 21957481

Bansal R, Prakash J, de Ruijter M, Beljaars L, Poelstra K. Peptide-modified
albumin carrier explored as a novel strategy for a cell-specific delivery of
interferon gamma to treat liver fibrosis. Mol Pharm. 2011 Oct 3;8(5):1899-909.
doi: 10.1021/mp200263q. Epub 2011 Aug 8. PubMed PMID: 21800888.

Bansal R, Post E, Proost JH, de Jager-Krikken A, Poelstra K, Prakash J.
PEGylation improves pharmacokinetic profile, liver uptake and efficacy of
Interferon gamma in liver fibrosis. J Control Release. 2011 Sep 25;154(3):233-40.
doi: 10.1016/j.jconrel.2011.05.027. Epub 2011 Jun 12. PubMed PMID: 21664391.

Bansal R, Prakash J, Post E, Beljaars L, Schuppan D, Poelstra K. Novel
engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice.
Hepatology. 2011 Aug;54(2):586-96. doi: 10.1002/hep.24395. Epub 2011 Jun 26.
PubMed PMID: 21538439.

Prakash J, de Jong E, Post E, Mohammad AK, Beljaars L, Poelstra K. Targeting
tumor stromal cells through a PDGF-beta receptor binding carrier. J Control
Release. 2010 Nov 20;148(1):e116. doi: 10.1016/j.jconrel.2010.07.088. PubMed
PMID: 21529587.

van Beuge MM, Prakash J, Lacombe M, Post E, Reker-Smit C, Beljaars L,
Poelstra K. Increased liver uptake and reduced hepatic stellate cell activation
with a cell-specific conjugate of the Rho-kinase inhibitor Y27632. Pharm Res.
2011 Aug;28(8):2045-54. doi: 10.1007/s11095-011-0430-9. Epub 2011 Mar 26. PubMed
PMID: 21442374; PubMed Central PMCID: PMC3130909.

van Beuge MM, Prakash J, Lacombe M, Gosens R, Post E, Reker-Smit C, Beljaars
L, Poelstra K. Reduction of fibrogenesis by selective delivery of a Rho kinase
inhibitor to hepatic stellate cells in mice. J Pharmacol Exp Ther. 2011
Jun;337(3):628-35. doi: 10.1124/jpet.111.179143. Epub 2011 Mar 7. PubMed PMID:
21383021.

Prakash J, de Jong E, Post E, Gouw AS, Beljaars L, Poelstra K. A novel
approach to deliver anticancer drugs to key cell types in tumors using a PDGF
receptor-binding cyclic peptide containing carrier. J Control Release. 2010 Jul
14;145(2):91-101. doi: 10.1016/j.jconrel.2010.03.018. Epub 2010 Mar 31. PubMed
PMID: 20362019.

Prakash J, Bansal R, Post E, de Jager-Krikken A, Lub-de Hooge MN, Poelstra K.
Albumin-binding and tumor vasculature determine the antitumor effect of
15-deoxy-Delta-(12,14)-prostaglandin-J(2) in vivo. Neoplasia. 2009
Dec;11(12):1348-58. PubMed PMID: 20019843; PubMed Central PMCID: PMC2794516.

Prakash J, Beljaars L, Harapanahalli AK, Zeinstra-Smith M, de Jager-Krikken
A, Hessing M, Steen H, Poelstra K. Tumor-targeted intracellular delivery of
anticancer drugs through the mannose-6-phosphate/insulin-like growth factor II
receptor. Int J Cancer. 2010 Apr 15;126(8):1966-1981. doi: 10.1002/ijc.24914.
PubMed PMID: 19795464.

de Borst MH, Prakash J, Sandovici M, Klok PA, Hamming I, Kok RJ, Navis G, van
Goor H. c-Jun NH2-terminal kinase is crucially involved in renal
tubulo-interstitial inflammation. J Pharmacol Exp Ther. 2009 Dec;331(3):896-905.
doi: 10.1124/jpet.109.154179. Epub 2009 Aug 28. PubMed PMID: 19717791.

Fretz MM, Dolman ME, Lacombe M, Prakash J, Nguyen TQ, Goldschmeding R, Pato
J, Storm G, Hennink WE, Kok RJ. Intervention in growth factor activated signaling
pathways by renally targeted kinase inhibitors. J Control Release. 2008 Dec
18;132(3):200-7. doi: 10.1016/j.jconrel.2008.08.013. Epub 2008 Aug 27. PubMed
PMID: 18793687.

Prakash J, de Borst MH, Lacombe M, Opdam F, Klok PA, van Goor H, Meijer DK,
Moolenaar F, Poelstra K, Kok RJ. Inhibition of renal rho kinase attenuates
ischemia/reperfusion-induced injury. J Am Soc Nephrol. 2008 Nov;19(11):2086-97.
doi: 10.1681/ASN.2007070794. Epub 2008 Jul 23. PubMed PMID: 18650485; PubMed
Central PMCID: PMC2573003.

Dolman ME, Fretz MM, Segers GJ, Lacombe M, Prakash J, Storm G, Hennink WE,
Kok RJ. Renal targeting of kinase inhibitors. Int J Pharm. 2008 Dec
8;364(2):249-57. doi: 10.1016/j.ijpharm.2008.04.040. Epub 2008 May 4. Review.
PubMed PMID: 18550305.

Prakash J, de Borst MH, van Loenen-Weemaes AM, Lacombe M, Opdam F, van Goor
H, Meijer DK, Moolenaar F, Poelstra K, Kok RJ. Cell-specific delivery of a
transforming growth factor-beta type I receptor kinase inhibitor to proximal
tubular cells for the treatment of renal fibrosis. Pharm Res. 2008
Oct;25(10):2427-39. doi: 10.1007/s11095-007-9515-x. Epub 2008 Jan 9. PubMed PMID:
18183478.

De Borst MH, Prakash J, Melenhorst WB, van den Heuvel MC, Kok RJ, Navis G,
van Goor H. Glomerular and tubular induction of the transcription factor c-Jun in
human renal disease. J Pathol. 2007 Oct;213(2):219-28. PubMed PMID: 17891746.

Temming K, Lacombe M, van der Hoeven P, Prakash J, Gonzalo T, Dijkers EC,
Orfi L, Kéri G, Poelstra K, Molema G, Kok RJ. Delivery of the p38 MAPkinase
inhibitor SB202190 to angiogenic endothelial cells: development of novel
RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug
linker technology. Bioconjug Chem. 2006 Sep-Oct;17(5):1246-55. PubMed PMID:
16984135.

Prakash J, Sandovici M, Saluja V, Lacombe M, Schaapveld RQ, de Borst MH, van
Goor H, Henning RH, Proost JH, Moolenaar F, Këri G, Meijer DK, Poelstra K, Kok
RJ. Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor
SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in
renal tubular cells: a novel strategy to treat renal fibrosis. J Pharmacol Exp
Ther. 2006 Oct;319(1):8-19. Epub 2006 Jun 28. PubMed PMID: 16807361.

Prakash J, Saluja V, Visser J, Moolenaar F, Meijer DK, Poelstra K, Kok RJ.
Bioanalysis and pharmacokinetics of the p38 MAPkinase inhibitor SB202190 in rats.
J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Nov 5;826(1-2):220-5. Epub
2005 Sep 23. PubMed PMID: 16183336.

Windt WA, Prakash J, Kok RJ, Moolenaar F, Kluppel CA, de Zeeuw D, van Dokkum
RP, Henning RH. Renal targeting of captopril using captopril-lysozyme conjugate
enhances its antiproteinuric effect in adriamycin-induced nephrosis. J Renin
Angiotensin Aldosterone Syst. 2004 Dec;5(4):197-202. PubMed PMID: 15803438.

Prakash J, Kok RJ, van Loenen-Weemaes A, Haas M, Proost JH, Meijer DK,
Moolenaar F. Renal targeting of captopril using subcutaneous administration of
captopril-lysozyme conjugate. J Control Release. 2005 Jan 3;101(1-3):350-1.
PubMed PMID: 15765569.

Prakash J, van Loenen-Weemaes AM, Haas M, Proost JH, Meijer DK, Moolenaar F,
Poelstra K, Kok RJ. Renal-selective delivery and angiotensin-converting enzyme
inhibition by subcutaneously administered captopril-lysozyme. Drug Metab Dispos.
2005 May;33(5):683-8. Epub 2005 Jan 26. PubMed PMID: 15673598.